Incyte Corporation (INCY) Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients With Myelofibrosis
6/17/2013 9:37:53 AM
More...
|
Incyte Corporation (INCY) Release: Jakafi® (ruxolitinib) Prescribing Information Updated With Expanded Dosing Guidance and New Safety Information
6/13/2013 10:25:15 AM
More...
|
Eli Lilly and Company (LLY), Incyte Corporation (INCY) Arthritis Pill Effective in Mid-Stage Study
6/13/2013 7:07:26 AM
More...
|
Incyte Corporation (INCY) Release: Data Presented at 2013 American Society of Clinical Oncology Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Bone Marrow Fibrosis, a Key Marker of Worsening Disease in Patients with Myelofibrosis
6/4/2013 7:41:04 AM
More...
|
Incyte Corporation (INCY) to Present at Upcoming Investor Conferences
5/22/2013 7:00:38 AM
More...
|
Incyte Corporation (INCY) to Present at Upcoming Investor Conferences
5/3/2013 7:53:57 AM
More...
|
Incyte Corporation (INCY) Reports First-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs
5/2/2013 8:14:13 AM
More...
|
Incyte Corporation (INCY) Earns a $25 Million Milestone Payment From Novartis AG (NVS)
4/29/2013 7:07:32 AM
More...
|
Incyte Corporation (INCY) to Report First Quarter 2013 Financial Results on May 2
4/11/2013 7:00:45 AM
More...
|
Gliknik Inc. Adds Incyte Corporation (INCY) President & CEO Paul A. Friedman to its Board of Directors
2/25/2013 8:56:34 AM
More...
|
|